

1 **How Should COVID-19 Vaccines be Distributed between the Global North and South?**  
2 **A Discrete Choice Experiment in Six European Countries**

3  
4  
5 **JJ Steinert**<sup>§\*</sup>, DPhil, TUM School of Social Sciences & Technology and TUM School of  
6 Medicine, Richard-Wagner Str. 1, 80333 München, Technical University of Munich, Munich,  
7 Germany, [janina.steinert@tum.de](mailto:janina.steinert@tum.de), phone: +4915784562543, Twitter: @jsteinert

8  
9 **H Sternberg**<sup>\*</sup>, MSc, TUM School of Social Sciences & Technology, Technical University of  
10 Munich, Munich, Germany

11  
12 **GA Veltri**, PhD, University of Trento, Trento, Italy

13  
14 **T Büthe**, PhD, TUM School of Social Sciences & Technology and TUM School of  
15 Management, Technical University of Munich, Munich, Germany; Kenan Institute for Ethics,  
16 Duke University

17  
18 <sup>§</sup>*corresponding author*

19 <sup>\*</sup>*joint first authors*

20 **Abstract**

21 **Background:** The global distribution of COVID-19 vaccinations remains highly unequal. We  
22 examine public preferences in six European countries regarding the allocation of COVID-19  
23 vaccines between the Global South and Global North.

24  
25 **Methods:** We conducted online discrete choice experiments with adult participants in France  
26 (n=766), Germany (n=1964), Italy (n=767), Poland (n=670), Spain (n=925), and Sweden  
27 (n=938). Respondents were asked to decide which one of two candidates, who varied along  
28 four attributes: age, mortality risk, employment, and living in a low- or high-income country,  
29 should receive the vaccine first. We analysed the relevance of each attribute in allocation  
30 decisions using a conditional logit regression.

31  
32 **Results:** Across countries, respondents selected candidates with a high mortality and infection  
33 risk, irrespective of whether the candidate lived in their own country. All else equal,  
34 respondents in Italy, France, Spain, and Sweden gave priority to a candidate from a low-income  
35 country, whereas German respondents were significantly more likely to choose the candidate  
36 from their own country. Female, younger, and more educated respondents were more  
37 favourable of an equitable vaccine distribution.

38  
39 **Conclusions:** Given these preferences for global solidarity, European governments should  
40 promote vaccine transfers to poorer world regions.

41  
42 **Funding:** Funding was provided by the European Union's Horizon H2020 research and  
43 innovation programme under grant agreement 101016233 (PERISCOPE).

44  
45 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

46 **Introduction**

47 In his opening speech to address the United Nations General Assembly in September 2021,  
48 Secretary General António Guterres expressed stark discontent with the highly unequal global  
49 distribution of COVID-19 vaccines: “*A majority of the wealthier world is vaccinated. Over 90*  
50 *percent of Africans are still waiting for their first dose. This is a moral indictment of the state*  
51 *of our world. It is an obscenity.*”(UN Secretary General, 2021). At the time of writing, only  
52 10% of citizens in low-income countries have received at least one dose of a COVID-19  
53 vaccine, while more than 80% of available doses have been allocated to people in high-income  
54 countries.(Padma, 2021) This blatant inequity in access to COVID-19 vaccines is partly a  
55 consequence of widespread vaccine nationalism in high-income countries, including the  
56 stockpiling of vaccine doses for their own citizens.(Harman et al., 2021; Herzog et al., 2021;  
57 Wagner et al., 2021)

58  
59 To ensure “fair and equitable access” to COVID-19 vaccines for all countries, the World Health  
60 Organisation (WHO), the Vaccine Alliance (Gavi), and the Coalition for Epidemic  
61 Preparedness Innovations (CEPI) formed a multilateral initiative named “COVID-19 Vaccines  
62 Global Access” (COVAX).(Herzog et al., 2021) However, several governments have resorted  
63 to making bilateral purchasing agreements with vaccine manufacturers outside of COVAX,  
64 which has substantially weakened the initiatives’ collective purchasing power.(Kim, 2021;  
65 Wouters et al., 2021) Moreover, recent estimates published by “Think Global Health” suggest  
66 that only a small fraction of the promised vaccine doses have actually reached people in low-  
67 income countries. The WHO’s pledges for a more equitable COVID-19 vaccine distribution  
68 have not been fulfilled.

69

70 Ramping up global COVID-19 vaccination rates is imperative for three reasons. From an  
71 ethical perspective, unequal access to vaccination leads to high rates of transmission, severe  
72 infections, and deaths in those parts of the world where health care capacity is the lowest. This  
73 aggravates existing health inequities between the Global South and North.(Godlee, 2021; Katz  
74 et al., 2021; Krause et al., 2021; Wagner et al., 2021) In addition, achieving a more equitable  
75 vaccine distribution would have utilitarian benefits: A recent modeling study compared two  
76 hypothetical scenarios – one in which the 50 richest countries used all available vaccines and  
77 one in which vaccines were allocated to all countries proportionally to their population size –  
78 finding that the former scenario would lead to twice as many COVID-19 deaths.(Herzog et al.,  
79 2021) Second, there are compelling economic arguments in favour of equitable vaccine  
80 distribution: The RAND Corporation estimates that constrained access to COVID-19 vaccines  
81 in low- and middle-income countries (LMICs) would reduce the global GDP by US\$ 153  
82 billion each year, including a loss of US\$ 56 billion in the European Union and United States  
83 combined.(Hafner et al., 2020) Put differently, every US\$ 1 spent on supplying vaccines to  
84 LMICs would yield a return of US\$ 4.8.(Hafner et al., 2020) Third, alleviating global  
85 asymmetries in COVID-19 vaccine coverage is warranted for virologic reasons. Unmitigated  
86 COVID-19 transmissions in some parts of the world will create evolutionary reservoirs from  
87 which new SARS-CoV-2 variants could arise, increasing the risk of immune escape - for both  
88 vaccine-induced and natural immunity - and of other phenotypic changes that could lead to  
89 greater virulence.(Saad-Roy et al., 2021; Telenti et al., 2021; van Oosterhout et al., 2021;  
90 Wagner et al., 2021) As WHO Director General Tedros Adhanom Ghebreyesus put it: “none  
91 of us will be safe until everyone is safe”.(UN Secretary General, 2021b)

92

93 Decision-makers in high-income countries are incentivised to engage in vaccine nationalism if  
94 there is limited public support for giving COVID-19 vaccines to poorer regions of the

95 world.(Clarke et al., 2021) Public opinion can be affected by populist rhetoric from nationalist  
96 parties, portraying vaccine donations to the Global South as a lack of patriotism. Governments  
97 will likely only donate vaccines or actively participate in international vaccine alliances such  
98 as COVAX if they do not expect to pay a price at the ballot box. A thorough understanding of  
99 public preferences for the global distribution of COVID-19 vaccines is therefore paramount.

100

101 Recent empirical literature has explored public preferences for the allocation of COVID-19  
102 vaccines. A majority of these studies examined public opinion on *prioritisation within* high-  
103 income countries and when COVID-19 vaccine availability was still heavily constrained in  
104 those countries.(Duch et al., 2021; Gollust et al., 2020; Knotz et al., 2021; Luyten et al., 2020;  
105 Persad et al., 2021; Reeskens et al., 2021; Sprengholz et al., 2021) Based on data from online  
106 surveys and survey experiments, the studies revealed substantial public support for prioritising  
107 frontline healthcare workers and clinically vulnerable groups.(Duch et al., 2021; Persad et al.,  
108 2021) To our knowledge, only four studies to date have examined individuals' preferences on  
109 the distribution of COVID-19 vaccines across national borders.(Clarke et al., 2021; Guidry et  
110 al., 2021; Klumpp et al., 2021; Vanhuyse et al., 2021) One online survey conducted in seven  
111 high-income countries found that around 50% of participants generally supported global  
112 allocation schemes that would give priority to the countries that could not afford to purchase  
113 vaccines.(Clarke et al., 2021) Another survey conducted in the US found that 40% of  
114 respondents were in favour of donating at least 10% of the nationally purchased vaccines to  
115 poorer countries. Support was less pronounced among older respondents – a group that is at  
116 greater risk of severe disease progression if infected.(Guidry et al., 2021)

117

118 A survey conducted in Germany asked participants to choose between different options for  
119 international agreements and alliances on the distribution of COVID-19 vaccines, which varied

120 by (i) countries joining the agreement, (ii) distribution rules, and (iii) cost per German  
121 household. The authors found that participants displayed a strong preference for an alliance  
122 exclusively composed of EU states. More importantly, the authors found that participants were  
123 more supportive of vaccine alliances if the national cost of participation was lower and national  
124 vaccine coverage higher, suggesting that participants' preferences were significantly shaped  
125 by self-interest.(Vanhuyse et al., 2021)

126

127 In contrast, in a discrete choice experiment conducted in Germany and the US, participants in  
128 both countries expressed a strong preference for prioritising vaccine allocation to countries  
129 with a higher number of COVID-19 deaths and fewer intensive care unit beds, even when they  
130 were asked to imagine that they or a vulnerable family member were still waiting for the  
131 COVID-19 vaccine.(Klumpp et al., 2021) Notably, no previous study to date has exclusively  
132 sampled participants who were still waiting for their first COVID-19 vaccine dose when  
133 participating in the survey experiment.

134

135 In this paper, we analyse new experimental evidence from six EU countries on citizens'  
136 preferences for the distribution of COVID-19 vaccines between the Global South and North.  
137 We advance the literature in three ways. First, by covering six countries, we implement the  
138 largest survey experiment on international vaccine allocation preferences to date and are thus  
139 able to examine differences in citizens' preferences across EU member states. Second, we  
140 conduct a discrete choice experiment among participants who are themselves not yet  
141 vaccinated, asking them to allocate a COVID-19 vaccine to either a person in their own country  
142 or to a person in a country in the Global South. This places specific salience on the notion that  
143 donating a vaccine dose to a person in the Global South might mean sacrificing one's own dose  
144 or that of a fellow citizen, thus leveraging self-interest-based and nationalistic considerations.

145 Third, we specifically examine heterogeneity in participants' preferences along key  
146 sociodemographic characteristics. Policymakers can use these insights to anticipate which  
147 population groups will be most and least supportive of COVID-19 vaccine donations.

## 148 **Results**

### 149 *Sample characteristics*

150  
151 A total of 6,030 eligible participants across all six countries completed the DCE. We excluded  
152 participants who did not reply to all of the eight choice tasks in the DCE. To that end, attrition  
153 across choice tasks ranged from 0% in Germany and Sweden, roughly 10% in France, Poland  
154 and Spain, to almost 15% in Italy. Table 1 presents socioeconomic characteristics of  
155 participants in each country. The German sample shows higher proportions of (i) older  
156 participants (age groups 55-64 and 65+ years), (ii) less educated participants, and (iii)  
157 participants with an increased risk of a severe COVID-19 infection. Cross-country differences  
158 in the sample compositions and deviations from the census statistics are probably linked to the  
159 timing of the survey launch and the vaccination progress in each country. The German survey  
160 was launched earlier, when a higher number of older people were not yet eligible for the  
161 COVID-19 vaccination and therefore were eligible to participate in the survey.

162

163

Table 1. Socio-demographic characteristics

	Germany	Spain	Italy	France	Poland	Sweden
<b>Female</b>	938 (47.76%)	471 (50.92%)	363 (47.33%)	376 (49.09%)	365 (54.48%)	465 (49.57%)
<b>Age group</b>						
18-24	148 (7.54%)	111 (12.00%)	107 (13.95%)	106 (13.84%)	185 (27.61%)	104 (11.09%)
25-34	279 (14.21%)	259 (28.00%)	163 (21.25%)	191 (24.93%)	179 (26.72%)	268 (28.57%)
35-44	361 (18.38%)	307 (33.19)	162 (21.12%)	217 (28.33%)	152 (22.69%)	281 (29.96%)
45-54	376 (19.14%)	193 (20.86)	177 (23.08%)	236 (30.81%)	105 (15.67%)	179 (19.08%)
55-64	484 (24.64%)	52 (5.62%)	130 (16.95%)	16 (2.09%)	41 (6.12%)	97 (10.34%)
65+	316 (16.09%)	3 (0.32%)	4 (0.52%)	0 (0%)	8 (1.19%)	9 (0.96%)
<b>Education</b>						
Primary	631 (32.13%)	3 (0.32%)	27 (3.52%)	9 (1.17%)	17 (2.54%)	40 (4.26%)
Secondary	622 (31.67%)	171 (18.49%)	141 (18.38%)	79 (10.31%)	130 (19.40%)	311 (33.16%)
Higher	359 (18.28%)	264 (28.54%)	353 (46.02%)	301 (39.30%)	337 (50.30%)	159 (16.95%)
University degree	352 (17.92%)	487 (52.56%)	222 (28.94%)	377 (49.22%)	186 (27.76%)	428 (45.63%)
<b>Employed</b>	1,204 (61.30%)	647 (69.95%)	480 (62.58%)	579 (75.59%)	460 (68.66%)	753 (80.28%)
<b>CV-19 high-risk group</b>	1,041 (53.00%)	255 (27.57%)	204 (26.60%)	219 (28.59%)	256 (38.21%)	190 (20.26%)
<b>Elevated CV-19 threat perception</b>	1,056 (53.88%)	491 (53.08%)	434 (58.41%)	349 (45.56%)	222 (33.13%)	462 (49.25%)
Observations	1964	925	767	766	670	938

164

165

166

167

168

*Notes: The table shows sample characteristics of participants by country, reporting both the absolute number of participants as well as the relative proportion of the respective characteristic prevalent in the sample. 'CV-19' denotes 'COVID-19'.*

169 *Discrete Choice Experiment*

170

171 Table 2 summarises results for the main effects model, which shows, separately for each  
172 country, the impacts of the four attributes and levels on a candidate's likelihood of being chosen  
173 by the respondent to receive the COVID-19 vaccine first. In France, Italy, Spain, and Sweden,  
174 respondents, on average, chose the hypothetical candidate from the Global South over the  
175 hypothetical candidate from their own country to receive the vaccine first (Spain: OR: 1.79,  
176 95% CI: 1.55-2.06; Italy: OR: 1.74, 95% CI: 1.50-2.01; Sweden: OR: 1.43, 95% CI: 1.24-1.65;  
177 France: OR: 1.37, 95% CI: 1.18-1.59; all p-values<0.001). For German respondents, we  
178 observe the opposite pattern: candidates from the Global South had significantly lower odds of  
179 being chosen to receive the vaccine (OR: 0.69, 95% CI: 0.62-0.76, p-value<0.001). In Poland,  
180 a candidate's country of residence neither increased nor decreased the odds of being chosen to  
181 receive the vaccine (OR: 0.99, 95% CI: 0.86-1.15).

182

183 For the attribute of COVID-19 mortality risk, we observe a similar pattern in all surveyed  
184 countries: The odds of being chosen to receive the vaccine were between two and almost six  
185 times higher for a candidate with an increased COVID-19 mortality risk, relative to a candidate  
186 with an average risk. The effect was even more pronounced for a candidate with a strongly  
187 increased mortality risk (ranging from OR: 4.35, 95% CI: 3.65-5.19 in Poland to OR: 14.20,  
188 95% CI: 11.75-17.17 in Sweden; all p-values<0.001).

189

190 For employment status and age, we also observed largely similar patterns across countries:  
191 First, employed candidates who lost income due to the pandemic and candidates who were  
192 employed in essential services exhibited were significantly more likely to be chosen to receive  
193 the vaccine when compared to unemployed candidates. Second, in all countries, 40-year-old



194 candidates had slightly higher odds of being chosen to receive the vaccine than 20- or 60-year-  
195 old candidates.

196

197 Figure 1 illustrates the results of the heterogeneity analysis that was pooled across countries  
198 (see Tables S2-3 for exact coefficients by subgroup and interaction terms). The odds of  
199 choosing the candidate from the Global South rather than the candidate from the respondents'  
200 own country were significantly higher for female (OR of interaction: 1.22, 95% CI: 1.10-1.36,  
201 p-value<0.001) and more educated (OR of interaction: 1.63, 95% CI: 1.46-1.82, p-  
202 value<0.001) respondents, and significantly lower for older respondents (above 45 years) (OR  
203 of interaction: 0.68, 95% CI: 0.61-0.76, p-value<0.001). In contrast, respondents who were  
204 themselves at high risk of a severe COVID-19 disease progression were significantly less  
205 supportive of distributing the COVID-19 vaccine to a candidate from the Global South (OR of  
206 interaction: 0.70, 95% CI: 0.63-0.78, p-value<0.001). In the subgroup of employed  
207 respondents, the odds of distributing the vaccine to a candidate in the Global South were  
208 slightly lower than in the subgroup of unemployed respondents (OR of interaction: 0.89, 95%  
209 CI: 0.80-1.00, p-value=0.045). The degree of COVID-19 threat perception did not seem to  
210 significantly affect respondents' distribution preferences (OR of interaction: 1.10, 95% CI:  
211 0.99-1.22, p-value=0.071).

212

213  
214  
216

Table 2. Main attribute effects by country

<b>Outcome:</b> Choosing the respective candidate to receive the vaccine						
	Germany (1)	Spain (2)	Italy (3)	France (4)	Poland (5)	Sweden (6)
<b>Age</b>						
20 years	Reference category					
40 years	1.39*** [1.33,1.45]	1.25*** [1.17,1.33]	1.16*** [1.09,1.22]	1.15*** [1.08,1.22]	1.08* [1.02,1.14]	1.13*** [1.06,1.20]
60 years	0.87*** [0.83,0.90]	0.85*** [0.80,0.91]	0.88*** [0.84,0.94]	0.87*** [0.82,0.93]	0.85*** [0.80,0.91]	0.77*** [0.73,0.82]
80 years	0.81*** [0.73,0.90]	1.23** [1.06,1.43]	1.12 [0.94,1.33]	0.59*** [0.50,0.69]	0.94 [0.78,1.13]	0.70*** [0.61,0.81]
<b>COVID-19 mortality risk</b>						
Average	Reference category					
Increased	5.63*** [5.13,6.19]	3.05*** [2.66,3.50]	2.27*** [1.96,2.64]	4.54*** [3.88,5.31]	2.40*** [2.07,2.79]	5.67*** [4.91,6.56]
Strongly increased	13.23*** [11.64,15.03]	9.68*** [8.12,11.53]	4.36*** [3.69,5.15]	9.04*** [7.50,10.91]	4.35*** [3.65,5.19]	14.20*** [11.75,17.17]
<b>Employment situation</b>						
Not employed	Reference category					
Employed (guaranteed income)	1.30*** [1.18,1.42]	0.79** [0.68,0.92]	1.14 [0.99,1.32]	1.04 [0.89,1.22]	1.06 [0.91,1.24]	1.00 [0.87,1.16]
Employed (income losses)	2.37*** [2.19,2.56]	1.91*** [1.71,2.13]	1.67*** [1.49,1.87]	1.65*** [1.47,1.86]	1.36*** [1.21,1.53]	1.73*** [1.54,1.94]
Essential services	6.01*** [5.38,6.72]	4.05*** [3.50,4.70]	2.27*** [1.98,2.59]	2.74*** [2.33,3.22]	1.88*** [1.65,2.15]	4.22*** [3.57,4.99]
<b>Country of residence</b>						
Respondents' country	Reference category					
Global South	0.69*** [0.62,0.76]	1.79*** [1.55,2.06]	1.74*** [1.50,2.01]	1.37*** [1.18,1.59]	0.99 [0.86,1.15]	1.43*** [1.24,1.65]
Log likelihood	-14428.91	-7090.45	-6541.07	-5994.74	-5860.07	-6875.04
AIC	28875.82	14198.89	13100.14	12007.48	11738.15	13768.07
BIC	28951.02	14267.31	13166.88	12074.21	11803.67	13836.62
Pseudo R <sup>2</sup>	0.22	0.19	0.10	0.17	0.08	0.23
Observations	31424	14800	12272	12256	10720	15008

218  
219  
220  
221  
222


*Notes:* Coefficients are odds ratios based on conditional logit estimations with standard errors clustered at the individual level. Results to be interpreted relative to the indicated reference category. 95% confidence intervals in brackets. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ . Sample sizes reflect the eight choice tasks performed by each respondent.

223 Figure S3 and Tables S4-9 summarise the extent to which these patterns prevail in each country.  
224 The heterogeneities we identify were strongest in the German, Spanish, and Swedish samples.  
225 In the French and Italian sample, these patterns were prevalent, too, but not statistically  
226 significant. Interestingly, in terms of age, we found that older participants were relatively more  
227 supportive of distributing the vaccine to a candidate from the Global South in both countries.  
228 In the Italian sample, this effect was even statistically significant (OR of interaction: 1.34, 95%  
229 CI: 1.00-1.78, p-value=0.049). In the Polish survey, heterogeneity patterns were less clear, and  
230 we observed an opposite effect for educational attainment, with less educated respondents  
231 showing more pronounced preferences for an equitable vaccine distribution (OR of interaction:  
232 0.72, 95% CI: 0.52-0.99, p-value=0.044).

233

234

235 Figure 1. Heterogeneity of country attribute by respondent characteristics (pooled sample)



236  
237  
238

## 239 Discussion

240

241 In our DCE conducted online in six EU countries, we found widespread global solidarity and  
242 support for a more equitable distribution of COVID-19 vaccines between the Global North and  
243 South. Our results point to vaccine allocation preferences that are largely driven by the assessed  
244 vulnerability of possible recipients, irrespective of whether the recipient lives in the  
245 respondents' own country or in the Global South. Similar to their prioritisation preferences  
246 *within* a country, our respondents – who are themselves not yet vaccinated against COVID-19  
247 but do favour vaccination – appear to rely upon the same solidarity considerations when  
248 vaccines are distributed *between* countries. For example, they choose the candidate with the  
249 higher mortality risk over the candidate with the same nationality. In addition, we find that in  
250 a situation of vaccine scarcity and all else being equal, respondents from Spain, Italy, France  
251 and Sweden would prefer to allocate the vaccine to a person living in a country in the Global  
252 South with a worse health care system, as opposed to a person living in their own country of  
253 residence. We thus confirm the findings of studies of citizens' distributional preferences,  
254 which revealed largely positive attitudes towards vaccine donations to poorer countries in the  
255 context of other pandemics (Kumar et al., 2012; Ritvo et al., 2013) and showed in experimental  
256 games that individuals follow egalitarian motives in their own decisions, (Dawes et al., 2007)  
257 and are even willing to punish third parties for inequalitarian behaviour. (Fehr and Gächter, 2002)  
258 Yet, we go beyond previous studies by showing that such support for allocating vaccines to  
259 low-income countries with low healthcare system capacity holds across European countries  
260 from Spain to Sweden, even among respondents who had themselves not yet gotten vaccinated,  
261 and in the context of a pandemic with truly global reach, which by the time when we conducted  
262 our experiments had lasted for well more than a year.

263

264 At the same time, our findings were inconclusive for Polish respondents and diverged for the  
265 German DCE: German survey participants were significantly less willing to allocate the  
266 COVID-19 vaccine to a person living in the Global South than to a person living in their own  
267 country, thus revealing preferences consistent with vaccine nationalism.

268

269 There are several possible explanations for the strikingly contrasting findings in Germany.  
270 First, studies have repeatedly found in-group bias (or here: national bias) in distributional  
271 preferences.(Bernhard et al., 2006; Reese et al., 2012; Yudkin et al., 2016) Such in-group bias  
272 might explain why German respondents appear willing to allocate the COVID-19 vaccines to  
273 more vulnerable candidates (e.g., those with higher COVID-19 risks) within their own country  
274 but not to candidates living in the Global South, if German participants had more nationalistic  
275 preferences, lower altruism, or less pro-social attitudes than participants from the other five  
276 countries. We lack the data to test this possible explanation directly, but it seem unlikely:  
277 several cross-country analyses investigating nationalism, patriotism, and xenophobia have  
278 found German citizens to be among the least nationalistic in Europe.(Coenders et al., 2021;  
279 Lubbers and Coenders, 2017) German citizens also do not generally appear to be outliers  
280 among their European peers in terms of altruism or similar pro-sociality variables.(Fehr et al.,  
281 2021)

282

283 Second, respondents might have been influenced by heterogeneities in the pandemic situation  
284 across countries. In Germany, our experiment was implemented as the third pandemic wave  
285 peaked, whereas in the other countries, our DCEs were launched two months later, during a  
286 phase of relatively low daily case numbers. German respondents might therefore have felt a  
287 greater urgency about having faster access to vaccination – though our data does not show

288 evidence of a substantially higher reported COVID-19 threat perception among German  
289 respondents (see Table S10 and Figure S4).

290

291 Third, the findings could be a function of the differences in the timing of the surveys relative  
292 to the progress of national vaccination campaigns. A recent survey experiment found that  
293 individuals with a higher perceived rank in the global income distribution feel stronger pressure  
294 to donate.(Fehr et al., 2021) Extrapolating this dynamic to the context of our study, we might  
295 expect to see a higher individual inclination for vaccine donations in countries where the  
296 (perceived) vaccination rate is high by international standards. When the survey was fielded in  
297 Italy, France, Spain, Poland, and Sweden, the vaccination rate in those countries exceeded 50%  
298 (30%) for first (second) doses whereas in Germany it was only at 25% (8%) (see Table S9).  
299 This difference in domestic conditions may have affected the perceived scarcity of the  
300 COVID-19 vaccines between countries and the normative assessment thereof.

301

302 A number of limitations are worth noting. First, participants' preferences may partly be driven  
303 by cross-country variation in (1) COVID-19 infection and mortality rates, (2) COVID-19  
304 vaccination rates, and (3) the pandemic trajectory over time. Our analyses did not allow for any  
305 in-depth investigation of these factors. Second, on an individual level, there may be additional  
306 characteristics that explain approval or rejection of COVID-19 vaccine donations but were not  
307 captured in the survey, including (1) nationalistic attitudes, (2) altruistic preferences or  
308 (3) migration background. Third, our analysis points to a number of predictors of variation.  
309 However, they are not susceptible to experimental manipulation and should therefore not be  
310 interpreted as causal. Fourth, at the country level (except in Germany), we were not able to  
311 achieve our initial target sample sizes due to budget constraints. Thus, we likely only have  
312 adequate statistical power in the pooled analysis. Lastly and relatedly, sample sizes varied

313 across countries and statistical power was higher in the German survey than in the other five  
314 surveys. However, since we find statistically significant effects of the main attributes in all  
315 countries except from Poland, lack of statistical power might have been less of a concern.

316

317 Policymakers and global health scholars have condemned the unequitable distribution of  
318 COVID-19 vaccines between high- and low-income countries as “vaccine  
319 apartheid”.(Gonsalves and Yamey, 2021; Harman et al., 2021) Still, the World Health  
320 Organisation’s call for a moratorium on COVID-19 booster vaccinations in high-income  
321 countries in favour of prioritising first dose vaccinations in low-income countries went  
322 unheeded, at least in part out of a sense that donating vaccines to countries in the Global South  
323 lacks popular support and might even subject the government to electoral punishment.(Krause  
324 et al., 2021) The emergence of the new Omicron variant – and fears of potential future variants  
325 – emphasises once again the transboundary nature of the COVID-19 pandemic.  
326 Acknowledging this, governments in high-income countries should discard mitigation  
327 strategies that are guided by the premise of vaccine nationalism.(Vanhuysse et al., 2021)  
328 Findings from our study suggest that governments of European countries can rely on solid  
329 public approval for a more equitable vaccine distribution – especially among female, younger  
330 and more educated citizens. Public support for vaccine donations to the Global South may  
331 further increase once the specific COVID-19 risk groups have received their booster  
332 vaccination. More effective international policy initiatives to ensure efficient, adequate, and  
333 timely COVID-19 vaccine transfers to low-income countries are urgently needed.

334



## 335 **Materials and Methods**

### 336 *Study Sample*

337 We conducted an online survey experiment in six EU countries: France, Germany, Italy,  
338 Poland, Spain, and Sweden. The German survey was launched at the height of the third wave  
339 in April 2021; the other five surveys were carried out in June 2021, coinciding with a phase of  
340 low case numbers in each country (see Figure S1). In each country, we recruited respondents  
341 aged 18 years and older, drawing on online panels of the survey provider *Bilendi-Respondi*.  
342 We sampled participants based on quotas that were matched to the census population of each  
343 target country in terms of (1) gender, (2) age, (3) education, and (4) geographic location (e.g.,  
344 state or province within each country) (see Table S1 for the census statistics of the sampled  
345 countries). Participants were given an individual link to the survey, where they first received  
346 information about the study's purpose, data protection regulations, and voluntary participation.  
347 After completing the survey, participants received a voucher worth three to five Euros, which  
348 was distributed by the survey company.

### 349 *Survey Experiment*

350  
351 Discrete choice experiments (DCEs) are used to measure the relative importance of different  
352 characteristics that respondents weigh against each other when making certain  
353 choices.(Mangham et al., 2009) DCEs have emerged from the theoretical tradition of random  
354 utility theory and are based on the assumption that respondents express their preferences by  
355 choosing the alternative associated with the highest individual benefits or utility.(Hall et al.,  
356 2004) DCEs have advantages over other stated preference techniques, such as ranking or rating  
357 exercises, because they (i) more closely mimic real-world choice scenarios, (ii) reduce the  
358 cognitive complexity for respondents, and (iii) can elicit implicit preferences.(Mangham et al.,  
359 2009)

360

361 We used the DCE methodology to elicit participants' preferences on the allocation of a  
362 COVID-19 vaccine dose to a person in the Global North or to a person in the Global South.  
363 We presented eight different choice sets and asked respondents to choose whether Person A or  
364 Person B should receive the COVID-19 vaccine first. Respondents were told that the other  
365 candidate of each pair would have to wait substantially longer to receive their first vaccine  
366 dose. In each of the eight choice sets, one candidate was described as living in the country of  
367 residence of the respondent – i.e. a high-income country with high healthcare system capacity,  
368 and the other candidate was described as living in a low-income country with a low healthcare  
369 system capacity. The healthcare system capacity was explicitly mentioned in the two candidate  
370 profiles. Across choice sets, candidates' characteristics varied along three additional attributes,  
371 namely (1) age (20; 40; 60; 80 years), (2) individual COVID-19 mortality risk due to  
372 comorbidity and/or lifestyle (no increased risk; increased risk; strongly increased risk), and (3)  
373 employment status (not employed; employed and guaranteed income; employed and income  
374 losses due to COVID-19 restrictions; employed in essential services).

375

376 The specific combination of candidate profiles in the eight choice sets, i.e., the experimental  
377 design (presented in Table 4) was selected for statistical efficiency (referred to as “D-  
378 efficiency”), which is accomplished by minimising the asymptotic variance-covariance matrix  
379 of the parameter estimates (based on an algorithm implemented in the software Ngene).(Reed  
380 Johnson et al., 2013) A sample choice situation as presented to respondents in the online survey,  
381 along with further technical information, is shown in Figure S2 and notes.

382

383

Table 4. Full list of choice sets of the DCE

Choice set	Age in years	COVID-19 mortality risk	Employment status	Country of residence and healthcare system capacity
1 Person A	40	No increased risk due to comorbidity and/or lifestyle	Not employed	[Respondents' country of residence], with high healthcare system capacity
1 Person B	40	Strongly increased risk due to comorbidity and/or lifestyle	Employed and guaranteed income	Low-income country, with poor healthcare system capacity)
2 Person A	60	Strongly increased risk due to comorbidity and/or lifestyle	Employed and guaranteed income	[Respondents' country of residence], with high healthcare system capacity
2 Person B	60	No increased risk due to comorbidity and/or lifestyle	Employed in essential services	Low-income country, with poor healthcare system capacity)
3 Person A	60	Increased risk due to comorbidity and/or lifestyle	Employed and income losses due to COVID-19 restrictions	[Respondents' country of residence], with high healthcare system capacity
3 Person B	80	Increased risk due to comorbidity and/or lifestyle	Not employed	Low-income country, with poor healthcare system capacity
4 Person A	20	Increased risk due to comorbidity and/or lifestyle	Employed in essential services	Low-income country, with poor healthcare system capacity
4 Person B	40	No increased risk due to comorbidity and/or lifestyle	Employed and income losses due to COVID-19 restrictions	[Respondents' country of residence], with high healthcare system capacity
5 Person A	40	No increased risk due to comorbidity and/or lifestyle	Employed in essential services	[Respondents' country of residence], with high healthcare system capacity
5 Person B	20	Increased risk due to comorbidity and/or lifestyle	Not employed	Low-income country, with poor healthcare system capacity
6 Person A	20	Strongly increased risk due to comorbidity and/or lifestyle	Employed and income losses due to COVID-19 restrictions	Low-income country, with poor healthcare system capacity
6 Person B	20	No increased risk due to comorbidity and/or lifestyle	Employed and guaranteed income	[Respondents' country of residence], with high healthcare system capacity
7 Person A	80	Increased risk due to comorbidity and/or lifestyle	Not employed	Low-income country, with poor healthcare system capacity
7 Person B	60	Increased risk due to comorbidity and/or lifestyle	Employed and income losses due to COVID-19 restrictions	[Respondents' country of residence], with high healthcare system capacity
8 Person A	40	No increased risk due to comorbidity and/or lifestyle	Employed and guaranteed income	Low-income country, with poor healthcare system capacity
8 Person B	40	Strongly increased risk due to comorbidity and/or lifestyle	Employed in essential services	[Respondents' country of residence], with high healthcare system capacity

384 *Notes: [Respondents' country of residence] was differed depending on the respective country the*  
 385 *survey was fielded in, e.g., in the German sample, this attribute level was 'Germany, with high*  
 386 *healthcare system capacity'. The design was determined with a built-in constraint for the attributes*  
 387 *Age and Employment status in order to avoid implausible combinations (specifically, an age of 80*  
 388 *was always combined with not being employed.*  
 389

390 Participants were only eligible to participate in the survey experiment if they (1) had not yet  
 391 been vaccinated against COVID-19 at the time of the survey and (2) indicated that they were  
 392 willing to get vaccinated. We employed these two criteria to elicit prioritisation preferences on  
 393 how to distribute scarce COVID-19 vaccine doses among individuals who perceived the  
 394 vaccine as beneficial *and* were themselves still waiting to receive their first dose. Thus, the

395 decisions of participants in the survey experiment might to a larger extent be informed by the  
396 fear/worry of having to sacrifice their own chances of getting a vaccine.

397

398 Power calculations for the discrete choice experiment indicated a desired sample size  
399 of  $n=2,061$  respondents per country.(de Bekker-Grob et al., 2015) However, the rapidly  
400 evolving pandemic situation in combination with conditional eligibility on vaccination status  
401 (see above) only allowed us to reach the required sample size in Germany due to the earlier  
402 timing of the data collection. Sample sizes in the remaining countries ranged from 670 in  
403 Poland to 925 in Spain, resulting in a total sample size of 6,030 eligible responses.

404

#### 405 *Heterogeneity Variables*

406 Similar to previous studies,(Duch et al., 2021; Persad et al., 2021) we examined the effect of  
407 the attribute ‘Country of residence’ for heterogeneity in terms of respondents’ socioeconomic  
408 characteristics. Specifically, we assessed whether respondents’ (i) gender, (ii) age, (iii)  
409 education, (iv) individual COVID-19 risk status, (v) COVID-19 threat perception, and (vi)  
410 employment status predicted differences in their allocation choices. Considering the limited  
411 statistical power within countries, the heterogeneity analysis was conducted with the pooled  
412 sample.

#### 413 *Statistical Analyses*

414

415 The empirical analysis comprised three steps. First, we estimated the main effects model for  
416 each country separately to assess the impact of the four candidate attributes (country of  
417 residence, age, COVID-19 mortality risk, employment status) on the probability of choosing a  
418 specific candidate. For each of the six countries, we estimated a conditional logit model by  
419 regressing the respondents’ allocation choice on the attribute levels of the candidate. Second,  
420 we examined heterogeneity in the effect of the country of residence attribute by adding

421 interaction terms between country of residence and heterogeneity variables to the above  
422 regression. A pre-analysis plan along with justifications of any deviations thereof is accessible  
423 via <https://osf.io/72jrql/>.

#### 424 ***Ethical Approval***

425  
426 The study received approvals from the ethics committees of the medical faculty at the Technical  
427 University of Munich (TUM, IRB 227/20 S) and the ethics board at the University of Trento  
428 (Trento, IRB 2021-027).

429

#### 430 **Acknowledgements**

431 We thank everyone who helped with translating: Walter Osika, Jocelyn Raude, Jonathan Garcia  
432 Fuentes, Anna Glyk, and Kathrin and Michal Bartoszewski. This project was funded by the  
433 European Union's Horizon 2020 research and innovation programme under grant agreement  
434 No 101016233 PERISCOPE). We are grateful for helpful comments on the analysis and  
435 interpretation made by Philipp Lergetporer, Michael Kurschilgen and Abu Siddique.

436

#### 437 **Competing interests**

438 The authors have no competing interests to declare.

#### 439 **Author contributions**

440 GAV, TB, and JIS acquired funding for this research study. JIS, HS and TB conceptualised  
441 and led the study and developed the pre-analysis plan. JIS, GAV and HS oversaw and managed  
442 the data collection. JIS and HS merged and cleaned the data, and HS conducted the data  
443 analyses and data visualisations. JIS, HS, TB, and GAV contributed to the interpretation of the  
444 quantitative findings. JIS and HS drafted the first version of the manuscript and all authors  
445 provided substantial revisions and feedback. We confirm that all authors have read and  
446 approved the final version of the manuscript.

447

#### 448 **Data availability statement**

449 A pre-analysis plan along with justifications of any deviations thereof is accessible via the  
450 Open Science Framework website: <https://osf.io/72jrql/>. All data and code will be shared via  
451 the same website.

## 452 References

453

- 454 Bernhard, H., Fischbacher, U., Fehr, E., 2006. Parochial altruism in humans. *Nature* 442,  
455 912–915. <https://doi.org/10.1038/nature04981>
- 456 Clarke, P.M., Roope, L.S.J., Loewen, P.J., Bonnefon, J.-F., Melegaro, A., Friedman, J.,  
457 Violato, M., Barnett, A., Duch, R., 2021. Public opinion on global rollout of COVID-  
458 19 vaccines. *Nat Med* 27, 935–936. <https://doi.org/10.1038/s41591-021-01322-9>
- 459 Coenders, M., Lubbers, M., Scheepers, P., 2021. Nationalism in Europe: Trends and Cross-  
460 national Differences in Public Opinion. *European Review* 29, 484–496.  
461 <https://doi.org/10.1017/S1062798720000526>
- 462 Dawes, C.T., Fowler, J.H., Johnson, T., McElreath, R., Smirnov, O., 2007. Egalitarian  
463 motives in humans. *Nature* 446, 794–796.
- 464 de Bekker-Grob, E.W., Donkers, B., Jonker, M.F., Stolk, E.A., 2015. Sample Size  
465 Requirements for Discrete-Choice Experiments in Healthcare: a Practical Guide.  
466 *Patient* 8, 373–384. <https://doi.org/10.1007/s40271-015-0118-z>
- 467 Duch, R., Roope, L.S.J., Violato, M., Becerra, M.F., Robinson, T.S., Bonnefon, J.-F.,  
468 Friedman, J., Loewen, P.J., Mamidi, P., Melegaro, A., Blanco, M., Vargas, J., Seither,  
469 J., Candio, P., Cruz, A.G., Hua, X., Barnett, A., Clarke, P.M., 2021. Citizens from 13  
470 countries share similar preferences for COVID-19 vaccine allocation priorities. *PNAS*  
471 118. <https://doi.org/10.1073/pnas.2026382118>
- 472 Fehr, D., Mollerstrom, J., Perez-Truglia, R., 2021. Your Place in the World - Relative Income  
473 and Global Inequality (SSRN Scholarly Paper No. ID 3832475). *Social Science*  
474 *Research Network*, Rochester, NY. <https://doi.org/10.2139/ssrn.3832475>
- 475 Fehr, E., Gächter, S., 2002. Altruistic punishment in humans. *Nature* 415, 137–140.  
476 <https://doi.org/10.1038/415137a>
- 477 Godlee, F., 2021. Vaccines should not be the preserve of rich countries. *BMJ* 374, n2044.  
478 <https://doi.org/10.1136/bmj.n2044>
- 479 Gollust, S.E., Saloner, B., Hest, R., Blewett, L.A., 2020. US Adults' Preferences for Public  
480 Allocation of a Vaccine for Coronavirus Disease 2019. *JAMA Netw Open* 3,  
481 e2023020. <https://doi.org/10.1001/jamanetworkopen.2020.23020>
- 482 Gonsalves, G., Yamey, G., 2021. The covid-19 vaccine patent waiver: a crucial step towards  
483 a “people’s vaccine.” *BMJ* 373, n1249. <https://doi.org/10.1136/bmj.n1249>
- 484 Guidry, J.P.D., Perrin, P.B., Laestadius, L.I., Vraga, E.K., Miller, C.A., Fuemmeler, B.F.,  
485 Burton, C.W., Ryan, M., Carlyle, K.E., 2021. U.S. public support for COVID-19  
486 vaccine donation to low- and middle-income countries during the COVID-19  
487 pandemic. *Vaccine* 39, 2452–2457. <https://doi.org/10.1016/j.vaccine.2021.03.027>
- 488 Hafner, M., Yerushalmi, E., Fays, C., Dufresne, E., Van Stolk, C., 2020. COVID-19 and the  
489 cost of vaccine nationalism. *RAND Corporation*.
- 490 Hall, J., Viney, R., Haas, M., Louviere, J., 2004. Using stated preference discrete choice  
491 modeling to evaluate health care programs. *Journal of Business Research* 57, 1026–  
492 1032.
- 493 Harman, S., Erfani, P., Goronga, T., Hickel, J., Morse, M., Richardson, E.T., 2021. Global  
494 vaccine equity demands reparative justice — not charity. *BMJ Global Health* 6,  
495 e006504. <https://doi.org/10.1136/bmjgh-2021-006504>
- 496 Herzog, L.M., Norheim, O.F., Emanuel, E.J., McCoy, M.S., 2021. Covax must go beyond  
497 proportional allocation of covid vaccines to ensure fair and equitable access. *BMJ*  
498 372, m4853. <https://doi.org/10.1136/bmj.m4853>

- 499 Katz, I.T., Weintraub, R., Bekker, L.-G., Brandt, A.M., 2021. From Vaccine Nationalism to  
500 Vaccine Equity - Finding a Path Forward. *N Engl J Med* 384, 1281–1283.  
501 <https://doi.org/10.1056/NEJMp2103614>
- 502 Kim, H., 2021. We need people’s WHO to solve vaccine inequity, and we need it now. *BMJ*  
503 *Global Health* 6, e006598. <https://doi.org/10.1136/bmjgh-2021-006598>
- 504 Klumpp, M., Monfared, I.G., Vollmer, S., 2021. To share or not to share – What the general  
505 public thinks about global COVID-19 vaccine distribution.  
506 <https://doi.org/10.1101/2021.08.16.21262116>
- 507 Knotz, C.M., Gandenberger, M.K., Fossati, F., Bonoli, G., 2021. Popular Attitudes Toward  
508 the Distribution of Vaccines Against COVID-19: The Swiss Case. *Swiss Political*  
509 *Science Review* 27, 297–310. <https://doi.org/10.1111/spsr.12461>
- 510 Krause, P.R., Fleming, T.R., Peto, R., Longini, I.M., Figueroa, J.P., Sterne, J.A.C., Cravioto,  
511 A., Rees, H., Higgins, J.P.T., Boutron, I., Pan, H., Gruber, M.F., Arora, N., Kazi, F.,  
512 Gaspar, R., Swaminathan, S., Ryan, M.J., Henao-Restrepo, A.-M., 2021.  
513 Considerations in boosting COVID-19 vaccine immune responses. *The Lancet* 398,  
514 1377–1380. [https://doi.org/10.1016/S0140-6736\(21\)02046-8](https://doi.org/10.1016/S0140-6736(21)02046-8)
- 515 Kumar, S., Quinn, S.C., Kim, K.H., Hilyard, K.M., 2012. US Public Support for Vaccine  
516 Donation to Poorer Countries in the 2009 H1N1 Pandemic. *PLOS ONE* 7, e33025.  
517 <https://doi.org/10.1371/journal.pone.0033025>
- 518 Lubbers, M., Coenders, M., 2017. Nationalistic attitudes and voting for the radical right in  
519 Europe. *European Union Politics* 18, 98–118.  
520 <https://doi.org/10.1177/1465116516678932>
- 521 Luyten, J., Tubeuf, S., Kessels, R., 2020. Who should get it first? Public preferences for  
522 distributing a COVID-19 vaccine. *Covid Economics, Vetted and Real-Time Papers*  
523 57.
- 524 Mangham, L.J., Hanson, K., McPake, B., 2009. How to do (or not to do) ... Designing a  
525 discrete choice experiment for application in a low-income country. *Health Policy*  
526 *Plan* 24, 151–158. <https://doi.org/10.1093/heapol/czn047>
- 527 Padma, T.V., 2021. COVID vaccines to reach poorest countries in 2023 - despite recent  
528 pledges. *Nature* 595, 342–343. <https://doi.org/10.1038/d41586-021-01762-w>
- 529 Persad, G., Emanuel, E.J., Sangenito, S., Glickman, A., Phillips, S., Largent, E.A., 2021.  
530 Public Perspectives on COVID-19 Vaccine Prioritization. *JAMA Netw Open* 4,  
531 e217943. <https://doi.org/10.1001/jamanetworkopen.2021.7943>
- 532 Reed Johnson, F., Lancsar, E., Marshall, D., Kilambi, V., Mühlbacher, A., Regier, D.A.,  
533 Bresnahan, B.W., Kanninen, B., Bridges, J.F.P., 2013. Constructing experimental  
534 designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis  
535 Experimental Design Good Research Practices Task Force. *Value Health* 16, 3–13.  
536 <https://doi.org/10.1016/j.jval.2012.08.2223>
- 537 Reese, G., Berthold, A., Steffens, M.C., 2012. We Are the World—and They Are Not:  
538 Prototypicality for the World Community, Legitimacy, and Responses to Global  
539 Inequality. *Political Psychology* 33, 683–700.
- 540 Reeskens, T., Roosma, F., Wanders, E., 2021. The perceived deservingness of COVID-19  
541 healthcare in the Netherlands: a conjoint experiment on priority access to intensive  
542 care and vaccination. *BMC Public Health* 21, 1–8. <https://doi.org/10.1186/s12889-021-10488-3>
- 544 Ritvo, P., Perez, D.F., Wilson, K., Gibson, J.L., Guglietti, C.L., Tracy, C.S., Bensimon, C.M.,  
545 Upshur, R.E., University of Toronto Joint Centre for Bioethics – Pandemic Ethics  
546 Working Group, 2013. Canadian national surveys on pandemic influenza  
547 preparations: pre-pandemic and peri-pandemic findings. *BMC Public Health* 13, 271.  
548 <https://doi.org/10.1186/1471-2458-13-271>

- 549 Saad-Roy, C.M., Morris, S.E., Metcalf, C.J.E., Mina, M.J., Baker, R.E., Farrar, J., Holmes,  
550 E.C., Pybus, O.G., Graham, A.L., Levin, S.A., Grenfell, B.T., Wagner, C.E., 2021.  
551 Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing  
552 regimes. *Science* 372, 363–370. <https://doi.org/10.1126/science.abg8663>
- 553 Sprengholz, P., Korn, L., Eitze, S., Betsch, C., 2021. Allocation of COVID-19 vaccination:  
554 when public prioritisation preferences differ from official regulations. *J Med Ethics*  
555 *medethics-2021-107339*. <https://doi.org/10.1136/medethics-2021-107339>
- 556 Telenti, A., Arvin, A., Corey, L., Corti, D., Diamond, M.S., García-Sastre, A., Garry, R.F.,  
557 Holmes, E.C., Pang, P.S., Virgin, H.W., 2021. After the pandemic: perspectives on  
558 the future trajectory of COVID-19. *Nature* 596, 495–504.  
559 <https://doi.org/10.1038/s41586-021-03792-w>
- 560 UN Secretary General, 2021. Secretary-General’s address to the 76th Session of the UN  
561 General Assembly | United Nations Secretary-General [WWW Document]. URL  
562 <https://www.un.org/sg/en/node/259283> (accessed 12.8.21).
- 563 UN Secretary General, 2021b. A global pandemic requires a world effort to end it – none of  
564 us will be safe until everyone is safe [WWW Document]. URL  
565 [https://www.who.int/news-room/commentaries/detail/a-global-pandemic-requires-a-](https://www.who.int/news-room/commentaries/detail/a-global-pandemic-requires-a-world-effort-to-end-it-none-of-us-will-be-safe-until-everyone-is-safe)  
566 [world-effort-to-end-it-none-of-us-will-be-safe-until-everyone-is-safe](https://www.who.int/news-room/commentaries/detail/a-global-pandemic-requires-a-world-effort-to-end-it-none-of-us-will-be-safe-until-everyone-is-safe) (accessed  
567 12.8.21).
- 568 van Oosterhout, C., Hall, N., Ly, H., Tyler, K.M., 2021. COVID-19 evolution during the  
569 pandemic - Implications of new SARS-CoV-2 variants on disease control and public  
570 health policies. *Virulence* 12, 507–508.  
571 <https://doi.org/10.1080/21505594.2021.1877066>
- 572 Vanhuyse, P., Jankowski, M., Tepe, M., 2021. Vaccine alliance building blocks: a conjoint  
573 experiment on popular support for international COVID-19 cooperation formats.  
574 *Policy Sci* 1–14. <https://doi.org/10.1007/s11077-021-09435-1>
- 575 Wagner, C.E., Saad-Roy, C.M., Morris, S.E., Baker, R.E., Mina, M.J., Farrar, J., Holmes,  
576 E.C., Pybus, O.G., Graham, A.L., Emanuel, E.J., Levin, S.A., Metcalf, C.J.E.,  
577 Grenfell, B.T., 2021. Vaccine nationalism and the dynamics and control of SARS-  
578 CoV-2. *Science* 373, eabj7364. <https://doi.org/10.1126/science.abj7364>
- 579 Wouters, O.J., Shadlen, K.C., Salcher-Konrad, M., Pollard, A.J., Larson, H.J.,  
580 Teerawattananon, Y., Jit, M., 2021. Challenges in ensuring global access to COVID-  
581 19 vaccines: production, affordability, allocation, and deployment. *Lancet* 397, 1023–  
582 1034. [https://doi.org/10.1016/S0140-6736\(21\)00306-8](https://doi.org/10.1016/S0140-6736(21)00306-8)
- 583 Yudkin, D.A., Rothmund, T., Twardawski, M., Thalla, N., Van Bavel, J.J., 2016. Reflexive  
584 intergroup bias in third-party punishment. *J Exp Psychol Gen* 145, 1448–1459.  
585 <https://doi.org/10.1037/xge0000190>  
586  
587